Rapid Zika Detection for Resource-Limited Regions | Mark Sharkey, PhD

HIV DART and Emerging Viruses 2016

(Abstract) In Silico Approaches Towards Broadly Active Flavivirus Protease Inhibitors | Bryan D. Cox

HIV DART and Emerging Viruses 2016

HIV-1 Macrophage Reservoirs: Lessons from Host Macrophage Specific Restriction Factor, SAMHD1 | Baek Kim, PhD

HIV DART and Emerging Viruses 2016

David Barry DART Achievement Award Lecture: The Discovery of SIV and Development of Monkey Models for the Study of HIV/ AIDS | Ronald Desrosiers, PhD

HIV DART and Emerging Viruses 2016

(Abstract) Differential responses of memory CD4+ T cell subsets to HIV latency reversing agents | D. Kulpa

HIV DART and Emerging Viruses 2016

(Abstract) HIV-1 dynamics under integrase inhibitor therapy suggests a subset of cells with slow integration | R.M. Ribeiro

HIV DART and Emerging Viruses 2016

Impact of Jak Inhibitors on HIV Reservoir Maintenance, Lifespan and Expansion in Primary T Cells and Macrophages | Christina Gavegnano, PhD

HIV DART and Emerging Viruses 2016

Current Clinical Therapies for HIV Remission | David Margolis, MD

HIV DART and Emerging Viruses 2016

(Abstract) Anti–HIV drug candidate abx464 prevents intestinal inflammation by producing IL22 in activated macrophages | J. Tazi

HIV DART and Emerging Viruses 2016

Gertrude Elion Distinguished Lecturer Award Lecture Stories on Scientific Discoveries that Transformed HIV into a Manageable Disease | Mark Wainberg, MD

HIV DART and Emerging Viruses 2016

(Abstract) Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) | B. Baugh

HIV DART and Emerging Viruses 2016

(Abstract) Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V | C. Callebaut

HIV DART and Emerging Viruses 2016

Management of Neurocognitive Impairment of Aging Populations Living with HIV | Scott Letendre, MD

HIV DART and Emerging Viruses 2016

Collateral Damage with Antiviral Therapy | David Thomas, MD, MPH

HIV DART and Emerging Viruses 2016

(Abstract) Case Control study of the oral microbiome in HIV uninfected individuals compared to HIV positive individuals before and after HAART | D. Malamud

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

The “Window of Opportunity”: Harnessing the Pediatric Immune Landscape for Life-Long Vaccine- Elicited Protection | Sallie Permar, MD, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

(Abstract) Enteric virome analysis of non-invasive samples from gorillas by next-generation sequencing and association with SIV infection | M. D’arc

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

Functional Role of Gut Microbiota in Chronic Liver Disease | Gary Wu, MD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

The Mycobiome and How it Influences Disease | Mahmoud Ghannoum, PhD, MBA

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

Live Biotherapeutics: How the Vaginal Microbiome Can be Modified to Prevent HIV Infection | Laurel Lagenaur, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

The NIH’s human microbiome project | Lita Proctor, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

The Human Microbiome and Cancer: New Opportunities For Population Studies | Emily Vogtmann, PhD, MPH

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

Oral microbiota in relation to HIV infection and oral infection in perinatally HIV-infected adolescents | Bruce Paster, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP

European HIV Clinical Forum 2016